KRAS and neoplasm: Insignificant but numerically longer OS was observed for patients with KRAS mutated tumours classified as CMS4 treated with bevacizumab (Fig. 5e, KRAS mutants: p = 0.24, HR = 0.66 [0.33–1.31]), with a median OS 28.3 months compared to 18.4 months when treated with cetuximab.